ALK and non-small cell lung carcinoma: Patients with advanced or metastatic NSCLC (mNSCLC) are suitable candidates for targeted therapies depending on the presence of actionable genomic alterations in driver oncogenes, such as EGFR, ALK, ROS1, and BRAF [3].